-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analysts Set Morphic Holding, Inc. (NASDAQ:MORF) Price Target at $64.43
Analysts Set Morphic Holding, Inc. (NASDAQ:MORF) Price Target at $64.43
Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) has earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $64.43.
MORF has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their target price on Morphic from $79.00 to $77.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. SVB Leerink began coverage on shares of Morphic in a research report on Wednesday, July 20th. They set an "outperform" rating and a $45.00 price target for the company. Royal Bank of Canada cut their price target on shares of Morphic from $76.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 4th. BMO Capital Markets restated a "buy" rating and set a $83.00 price target on shares of Morphic in a research report on Friday, August 5th. Finally, Stifel Nicolaus assumed coverage on shares of Morphic in a research report on Tuesday, September 6th. They set a "buy" rating and a $44.00 price target for the company.
Get Morphic alerts:Morphic Stock Down 1.6 %
MORF opened at $29.56 on Thursday. The stock has a market cap of $1.14 billion, a PE ratio of -20.67 and a beta of 1.46. Morphic has a 52 week low of $19.23 and a 52 week high of $68.75. The business's fifty day simple moving average is $27.87 and its 200 day simple moving average is $30.24.
Institutional Trading of Morphic
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Hong Kong Ltd increased its stake in shares of Morphic by 983.3% during the fourth quarter. Point72 Hong Kong Ltd now owns 715 shares of the company's stock valued at $34,000 after purchasing an additional 649 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Morphic during the second quarter valued at approximately $28,000. UBS Group AG bought a new stake in shares of Morphic during the first quarter valued at approximately $54,000. Group One Trading L.P. bought a new stake in shares of Morphic during the first quarter valued at approximately $56,000. Finally, Amalgamated Bank bought a new stake in shares of Morphic during the first quarter valued at approximately $138,000. 81.64% of the stock is currently owned by hedge funds and other institutional investors.Morphic Company Profile
(Get Rating)
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Morphic (MORF)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.
Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) has earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $64.43.
據Marketbeat.com報道，Moric Holding，Inc.(納斯達克代碼：Morf-Get Rating)目前覆蓋該公司的八家評級公司的平均推薦為買入。八位股票研究分析師已將該股評級為買入建議。在過去一年發佈該股報告的分析師中，平均一年目標價為64.43美元。
MORF has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their target price on Morphic from $79.00 to $77.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. SVB Leerink began coverage on shares of Morphic in a research report on Wednesday, July 20th. They set an "outperform" rating and a $45.00 price target for the company. Royal Bank of Canada cut their price target on shares of Morphic from $76.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 4th. BMO Capital Markets restated a "buy" rating and set a $83.00 price target on shares of Morphic in a research report on Friday, August 5th. Finally, Stifel Nicolaus assumed coverage on shares of Morphic in a research report on Tuesday, September 6th. They set a "buy" rating and a $44.00 price target for the company.
Morf已經成為許多研究分析師報告的主題。富國銀行在8月4日(星期四)的一份研究報告中將Morphy的目標價從79.00美元下調至77.00美元，並對該股設定了“增持”評級。7月20日星期三，SVB Leerink在一份研究報告中開始對Morphi的股票進行報道。他們為該公司設定了“跑贏大盤”的評級和45.00美元的目標價。8月4日，加拿大皇家銀行在一份研究報告中將Morphi的股票目標價從76.00美元下調至70.00美元，併為該公司設定了“跑贏大盤”的評級。蒙特利爾銀行資本市場在8月5日(星期五)的一份研究報告中重申了“買入”評級，併為Morphi的股票設定了83.00美元的目標價。最後，Stifel Nicolaus在9月6日(星期二)的一份研究報告中對Morphi的股票進行了報道。他們為該公司設定了“買入”評級和44.00美元的目標價。
Morphic Stock Down 1.6 %
Moric股票下跌1.6%
MORF opened at $29.56 on Thursday. The stock has a market cap of $1.14 billion, a PE ratio of -20.67 and a beta of 1.46. Morphic has a 52 week low of $19.23 and a 52 week high of $68.75. The business's fifty day simple moving average is $27.87 and its 200 day simple moving average is $30.24.
Morf週四開盤報29.56美元。該股市值為11.4億美元，市盈率為-20.67倍，貝塔係數為1.46。Moric的52周低點為19.23美元，52周高點為68.75美元。該業務的50日簡單移動均線切入位為27.87美元，200日簡單移動均線切入位為30.24美元。
Institutional Trading of Morphic
Morphi的機構交易
Morphic Company Profile
形態化的公司簡介
(Get Rating)
(獲取評級)
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
生物製藥公司Moric Holding，Inc.發現和開發用於治療自身免疫、心血管、代謝性疾病以及纖維化和癌症的口服小分子整合素療法。它的主要候選產品是Morf-057，這是一種A4？7特定的影響炎症的整合素抑制劑，目前處於治療炎症性腸病的第一階段臨牀試驗；以及治療特發性肺纖維化和纖維化疾病的臨牀前試驗。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Morphic (MORF)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於Morphy的研究報告(Morf)
- MarketBeat：回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦，這些股票可能表現優異
- DocuSign是否即將發生重大逆轉？
- 石油和天然氣股票：投資可再生能源的安全途徑
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.
接受Morphy Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Morphi及相關公司評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧